Cholinergic stimulation with pyridostigmine protects myocardial infarcted rats against ischemic-induced arrhythmias and preserves connexin43 protein

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 308, Issue 1, 2015, Pages 101-107

  Santos Almeida, Fernanda Machado ^a   Girão, Henrique ^b   Aguiar da Silva, Carlos Alberto ^a   Salgado, Helio Cesar ^a   Fazan, Rubens ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Anticholinesterase agent; Arrhythmias; Autonomic imbalance; Myocardial infarction; Parasympathetic stimulation

Indexed keywords

CONNEXIN 43; METHYLATROPINE; PROPRANOLOL; PYRIDOSTIGMINE; ATROPINE DERIVATIVE; CHOLINESTERASE INHIBITOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTERIAL PRESSURE; ARTICLE; CHOLINERGIC STIMULATION; CONTROLLED STUDY; DRUG MECHANISM; ELECTROCARDIOGRAPH ELECTRODE; HEART ARRHYTHMIA; HEART CATHETER; HEART HEMODYNAMICS; HEART INFARCTION; HEART PROTECTION; HEART RATE; MALE; NONHUMAN; PRIORITY JOURNAL; QTC INTERVAL; RAT; SYMPATHETIC TONE; ANIMAL; ARRHYTHMIAS, CARDIAC; BLOOD PRESSURE; DRUG EFFECTS; METABOLISM; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PHYSIOLOGY; VAGUS NERVE; WISTAR RAT;

ANIMALS; ARRHYTHMIAS, CARDIAC; ATROPINE DERIVATIVES; BLOOD PRESSURE; CHOLINESTERASE INHIBITORS; CONNEXIN 43; HEART RATE; MALE; MYOCARDIAL INFARCTION; PROPRANOLOL; PYRIDOSTIGMINE BROMIDE; RATS; RATS, WISTAR; VAGUS NERVE;

EID: 84920066843     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00591.2014     Document Type: Article

References (65)

1. Ahnvc S, Erhardt LR, Lindvall K, Lundman T, Sjogren A, Wahlberg I. Cardiac filling pressures in acute inferior myocardial infarction with and without right ventricular involvement. Eur J Cardiol 7: 125-130, 1978.
2. Ahnve S, Helmers C, Lundman T, Rchnqvist N, Sjogren A. QTc intervals in acute myocardial infarction: first-year prognostic implications. Clin Cardiol 3: 303-308, 1980.
3. Alves-Amaral G, Pires-Oliveira M, Andrade-Lopes AL, Chiavegatti T, Godinho RO. Gender-related differences in circadian rhythm of rat plasma acetyl- and butyrylcholinesterase: effects of sex hormone withdrawal. Chem Biol Interact 186: 9-15, 2010.
4. Ando M, Katarc RG, Kakinuma Y, Zhang D, Yamasaki F, Muramoto K, Sato T. Efferent vagal nerve stimulation protects heart against ischemia-induced arrhythmias by preserving connexin43 protein. Circulation 112: 164-170, 2005.
5. Behling A, Moraes RS, Rohde LE, Ferlin EL, Nohrega AC, Ribeiro JP. Cholinergic stimulation with pyridostigmine reduces ventricular arrhythmia and enhances heart rate variability in heart failure. Am Heart J 146: 494-500, 2003.
6. Bejarano E, Girao H, Yuste A, Patel B, Marques C, Spray DC, Pereira P, Cuervo AM. Autophagy modulates dynamics of connexins at the plasma membrane in a ubiquitin-dependent manner. Mot Bio J Cell 23: 2156-2169, 2012.
7. Brack KE, Coote JH, Ng GA. Vagus nerve stimulation protects against ventricular fibrillation independent of muscarinic receptor activation. Cardiovasc Res 91: 437-446, 2011.
8. Breyer-Pfaff U, Maier U, Brinkniann AM, Schumm F. Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis. Clin Pharmacol Ther 37: 495-501, 1985.
9. Castro RR, Porphirio G, Serra SM, Nobrega AC. Cholinergic stimulation with pyridostigmine reduces the QTc interval in coronary artery disease. Braz J. Med Biol Res 35: 685-689, 2002.
10. Castro RR, Serra SM, Nohrega AC. Reduction of QTc interval dispersion. Potential mechanism of cardiac protection of pyridostigmine bromide. Arq Bras Cardiol 75: 205-213, 2000.
11. Castro RR, Serra SM, Porphirio G, Mendes FS, Oliveira LP, Nobrega AC. Pyridostigmine reduces QTc interval during recovery from maximal exercise in ischemic heart disease. Int J Cardiol 107: 138-139, 2006.
12. Chaney LA, Roekhold RW, Hume AS. Cardiorespiratory effects following acute exposure to pyridostigmine bromide and/or N,N-diethyl-m- toluamide (DEET) in rats. Int J Toxicol 21: 287-300, 2002.
13. De Ferrari GM, Schwartz PJ. Vagus nerve stimulation: from pre-clinical to clinical application: challenges and future directions. Heart Fail Rev 16: 195-203, 2011.
14. de Pontes PV, Bastos BG, Romeo Filho LJ, Mesquita ET, da Nobrega AC. Cholinergic stimulation with pyridostigmine, hemodynamic and echocardiographic analysis in healthy subjects. Arq Bras Cardiol 72: 297-306, 1999.
15. Dewland TA, Androne AS, Lee FA, Lamport RJ, Katz SD. Effect of acetylcholinesterase inhibition with pyridostigmine on cardiac parasympathetic function in sedentary adults and trained athletes. Am J Physiol Heart Circ Physiol 293: H86-H92, 2007.
16. Doroghazi RM, Childers R. Time-related changes in the Q-T interval in acute myocardial infarction: possible relation to local hypocalcemia. Am J Cardiol 41: 684-688, 1978.
17. Fazan R Jr, de Oliveira M, Oliveira JA, Salgado HC, Garcia-Calrasco N. Changes in autonomic control of the cardiovascular system in the Wistar audiogenic rat (WAR) strain. Epilepsy Behav 22: 666-670, 2011.
18. Fernandes R, Girao H, Pereira P. High glucose down-regulates intercellular communication in retinal endothelial cells by enhancing degrada tion of connexin 43 by a proteasome-dependent mechanism. J Biol Chem 279: 27219-27224, 2004.
19. Goldberger JJ. Sympathovagal balance: how should we measure it? Am J Physiol Heart Circ Physiol 276: H1273-H1280, 1999.
20. Gutstein DE, Morley GE, Tamaddon H, Vaidya D, Schneider MD, Chen J, Chien KR, Stuhlmann H, Fishman GI. Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43. Circ Res 88: 333-339, 2001.
21. Hartikainen JE, Malik M, Staunton A, Poloniecki J, Camm AJ. Distinction between arrhythmic and nonarrhythmic death after acute myocardial infarction based on heart rate variability, signal-averaged electrocardiogram, ventricular arrhythmias and left ventricular ejection fraction. J Am Coll Cardiol 28: 296-304, 1996.
22. Haynes RE, Hallstrom AP, Cobb LA. Repolarization abnormalities in survivors of out-of-hospital ventricular fibrillation. Circulation 57: 654- 658, 1978.
23. Imai Y, Abe K, Sasaki S, Minami N, Munakata M, Yumita S, Nobunaga T, Sekino H, Yoshinaga K. Role of vasopressin in cardiovascular response to central cholinergic stimulation in rats. Hypertension 13: 549-557, 1989.
24. Johns TN, Olson BJ. Experimental myocardial infarction. I. A method of coronary occlusion in small animals. Ann Surf; 140: 675-682, 1954.
25. Johnston KM, MacLeod BA, Walker MJ. Responses to ligation of a coronary artery in conscious rats and the actions of antiarrhythmics. Can J Physiol Pharmacol 61: 1340-1353, 1983.
26. Kirchheim HR. Systemic arterial baroreceptor reflexes. Physiol Rev 56: 100-177, 1976.
27. Kochiadakis GE, Markctou ME, Igoumenidis NE, Simantirakis EN, Parthenakis FI, Manios EG, Vardas PE. Autonomic nervous system activity before and during episodes of myocardial ischemia in patients with stable coronary artery disease during daily life. Pacing Clin Electrophysiol 23: 2030-2039, 2000.
28. Knlettis TM, Agelaki MG, Baltogiannis GG, Vlahos AP, Mourouzis I, Fotopoulos A, Pantos C. Comparative effects of acute vs. chronic oral amiodarone treatment during acute myocardial infarction in rats. Europace 9: 1099-1104, 2007.
29. Kop WJ, Verdino RJ, Gottdiener JS, O'Leary ST, Bairey Mcrz CN, Krantz DS. Changes in heart rate and heart rate variability before ambulatory ischemic events. J Am Coll Cardiol 38: 742-749, 2001.
30. Kop WJ, Verdino RJ, Gottdiener JS, O'Leary ST, Bairey Merz CN, Krantz DS. Changes in heart rate and heart rate variability before ambulatory ischemic events(l). J Ant Coll Cardiol 38: 742-749, 2001.
31. Kupper W, Bleifeld W, Hanrath P, Mathey D, Eff'ert S. Left ventricular hemodynamics and function in acute myocardial infarction: studies during the acute phase, convalescence and late recovery. Am J Cardiol 40: 900-905, 1977.
32. Lampc PD, Lau AF. Regulation of gap junctions by phosphorylation of connexins. Arch Biochem Biophys 384: 205-215, 2000.
33. Lataro RM, Silva CA, Fazan R Jr, Rossi MA, Prado CM, Godinho RO, Salgado HC. Increase in parasympathetic tone by pyridostigmine prevents ventricular dysfunction during the onset of heart failure. Am J Physiol Regul Integr Comp Physiol 305: R908-R916, 2013.
34. Lerner DL, Yamada KA, Schuessler RB, Saffitz JE. Accelerated onset and increased incidence of ventricular arrhythmias induced by ischemia in Cx43-deficient mice. Circulation 101: 547-552, 2000.
35. Levy MN. Sympathetic-parasympathetic interactions in the heart. Circ Res 29: 437-445, 1971.
36. Li M, Zheng C, Sato T, Kawada T, Sugimachi M, Sunagawa K. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 109: 120-124, 2004.
37. Lowel H, Dobson A, Keil U, Herman B, Hobbs MS, Stewart A, Arstila M, Mietlinen H, Miistaniemi H, Tuomilehto J. Coronary heart disease case fatality in four countries. A community study. The Acute Myocardial Infarction Register Teams of Auckland, Augsburg, Bremen, FIN- MONICA, Newcastle, and Perth. Circulation 88: 2524-2531, 1993.
38. Mallíani A, Schwartz PJ, Zanchetti A. A sympathetic reflex elicited by experimental coronary occlusion. Am J Physiol 217: 703-709, 1969.
39. Mimica N, Presecki P. Side effects of approved anlidementives. Psychi- atr Danub 21: 108-113, 2009.
40. Musil LS, Goodenough DA. Biochemical analysis of connexin43 intracellular transport, phosphorylation, and assembly into gap junctional plaques. J Cell Biol 115: 1357-1374, 1991.
41. Nobrega AC, Carvalho AC, Bastos BG. Resting and reflex heart rate responses during cholinergic stimulation with pyridostigmine in humans. Braz J Med Biol Res 29: 1461-1465, 1996.
42. Nobrega AC, dos Reis AF, Moraes RS, Bastos BG, Ferlin EL, Ribeiro JP. Enhancement of heart rate variability by cholinergic stimulation with pyridostigmine in healthy subjects. Clin Auton Res 11:11-17, 2001.
43. Okazaki Y, Zheng C, Li M, Sugimachi M. Effect of the cholinesterase inhibitor donepezil on cardiac remodeling and autonomic balance in rats with heart failure. J Physiol Sci 60: 67-74, 2010.
44. Opitz CF, Mitchell GF, Pfeffer MA, Pfeffer JM. Arrhythmias and death after coronary artery occlusion in the rat. Continuous telemetric ECG monitoring in conscious, untethered rats. Circulation 92: 253-261, 1995.
45. Peters NS, Green CR, Poole-Wilson PA, Severs NJ. Reduced content of connexin43 gap junctions in ventricular myocardium from hypertrophied and ischemic human hearts. Circulation 88: 864-875, 1993.
46. Pfeffer MA, Pfeffer JM, Fishbein MC, Fletcher PJ, Spadaro J, Kloner RA, Braunwald E. Myocardial infarct size and ventricular function in rats. Circ Res 44: 503-512, 1979.
47. Poelzing S, Rosenbaum DS. Altered connexin43 expression produces arrhythmia substrate in heart failure. Am J Physiol Heart Circ Physiol 287: H1762-HI770, 2004.
48. Rahimtoola SH, DiGilio MM, Ehsani A, Loeb HS, Rosen KM, Gunnar RM. Changes in left ventricular performance from early after acute myocardial infarction to the convalescent phase. Circulation 46: 770-779, 1972.
49. Roger VL. Epidemiology of myocardial infarction. Med Clin North Am 91: 537-552, 2007.
50. Sabino JP, da Silva CA, de Melo RF, Fazan R Jr, Salgado HC. The treatment with pyridostigmine improves the cardiocirculatory function in rats with chronic heart failure. Auton Neurosci 173: 58-64, 2013.
51. Sato T, Nakatsuka H. [Anticholinesterases; peripheral and central effects], Masuì 62: 19-26, 2013.
52. Schwartz PJ, Wolf S. QT interval prolongation as predictor of sudden death in patients with myocardial infarction. Circulation 57: 1074-1077, 1978.
53. Soares PP, da Nobrega AC, Lshizima MR, Irigoyen MC. Cholinergic stimulation with pyridostigmine increases heart rate variability and baro- reflex sensitivity in rats. Auton Neurosci 113: 24-31, 2004.
54. Sroka K, Peimann CJ, Seevers H. Heart rate variability in myocardial ischemia during daily life. J Electrocardiol 30: 45-56, 1997.
55. Taylor P. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2001.
56. Tucker DC, Johnson AK. Development of autonomic control of heart rate in genetically hypertensive and normotensive rats. Am J Physiol Regul Integr Comp Physiol 246: R570-R577, 1984.
57. Vanhoutte PM, Levy MN. Prejunctional cholinergic modulation of adrenergic neurotransmission in the cardiovascular system. Am J Physiol Heart Circ Physiol 238: H275-H28I, 1980.
58. Vanoli E, De Ferrari GM, Stramba-Badiale M, Hull SS Jr, Foreman RD, Schwartz PJ. Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. Circ Res 68: 1471 1481, 1991.
59. Waxman MB, Wald RW. Termination of ventricular tachycardia by an increase in cardiac vagal drive. Circulation 56: 385-391, 1977.
60. Webb SW, Adgey AA, Pantridge JF. Autonomic disturbance at onset of acute myocardial infarction. Br Med J 3: 89-92, 1972.
61. White HD, Chew DP. Acute myocardial infarction. Lancet 372: 570- 584, 2008.
62. Zhang Y, Kakinuma Y, Ando M, Katare RG, Yamasaki F, Sugiura T, Sato T. Acetylcholine inhibits the hypoxia-induced reduction of con- nexin43 protein in rat cardiomyocytes. J Pharmacol Sci 101: 214-222, 2006.
63. Zhao J, Su Y, Zhang Y, Pan Z, Yang L, Chen X, Liu Y, Lu Y, Du Z, Yang B. Activation of cardiac muscarinic M3 receptors induces delayed cardioprotection by preserving phosphorylated connexin43 and up-regulating cyclooxygenase-2 expression. Br J Pharmacol 159: 1217-1225, 2010.
64. Zheng C, Li M, Inagaki M, Kawada T, Sunagawa K, Sugimachi M. Vagal stimulation markedly suppresses arrhythmias in conscious rats with chronic heart failure after myocardial infarction. Conf Proc IEEE Eng Med Biol Soc 7: 7072-7075, 2005.
65. Zimerman LI, Liberman A, Castro RR, Ribeiro JP, Nobrega AC. Acute electrophysiologic consequences of pyridostigmine inhibition of cholinesterase in humans. Braz J Med Biol Res 43: 211-216, 2010.